Skip to main
MEDP

Medpace Holdings (MEDP) Stock Forecast & Price Target

Medpace Holdings (MEDP) Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 0%
Buy 20%
Hold 80%
Sell 0%
Strong Sell 0%

Bulls say

Medpace Holdings is a global contract research organization (CRO) that focuses on providing full-service drug-development and clinical trial services to biotechnology, pharmaceutical, and medical device firms. The company has a diversified portfolio of services, including bioanalytical laboratory and imaging capabilities, and a strong presence in key international markets. The recent bookings inflection and normalization of cancellations, in addition to a strong pre-backlog pipeline, support a positive outlook for the company's continued gross bookings ramp into 2027. However, potential risks in the CRO space, such as changes in government regulations and macroeconomic weakness, should be closely monitored. Overall, with a strong underlying fundamentals and a potential for future growth, Medpace is a strong investment opportunity.

Bears say

Medpace Holdings is a full-service contract research organization that provides clinical trial services to biotech, pharmaceutical, and medical device companies. However, the company's recent improvement in net bookings is primarily due to lower cancellations rather than gross bookings growth, which may suggest a structural buffer against future cancellation spikes. Additionally, Medpace's high leverage to the biopharma industry and strong momentum in CRO utilization may be at risk due to government funding delays and potential challenges in sourcing clinical trial talent or materials. The company's focus on ethical conduct and diverse leadership team may be positives, but the concentration of revenue from a few large metabolic programs may present a risk to future revenue.

Medpace Holdings (MEDP) has been analyzed by 10 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 20% recommend Buy, 80% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medpace Holdings (MEDP) Forecast

Analysts have given Medpace Holdings (MEDP) a Hold based on their latest research and market trends.

According to 10 analysts, Medpace Holdings (MEDP) has a Hold consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $560.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $560.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medpace Holdings (MEDP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.